Colon Cancer Treatment by Stage

Colon cancer stage comes from the AJCC TNM system, 8th edition. Three separate questions get answered, then combined.

T is how deep the tumor has grown through the bowel wall. The wall has layers, and the T number tracks which one has been breached.

• Tis: carcinoma in situ, confined to the mucosa lining, not through the muscularis mucosae.
• T1: through the muscularis mucosae into the submucosa.
• T2: into the muscularis propria, the thick muscle layer.
• T3: through the muscularis propria into the fatty tissue around the colon.
• T4a: through the visceral peritoneum, the outer membrane.
• T4b: directly invading another organ or structure.

N is how many lymph nodes contain cancer.

• N0: no nodes involved.
• N1: one to three nodes positive, counting deposits of 0.2 mm or more.
• N2a: four to six nodes positive.

M is whether it has spread to distant sites. M0 means no, M1 means yes.

Combined: stage 0 is Tis N0 M0. Stage I is T1 or T2, N0, M0. Stage II is T3 or T4 with no nodes: IIA is T3, IIB is T4a, IIC is T4b. Stage III is any T with positive nodes. Stage IV is any M1.

One number on your pathology report is worth checking. Guidance calls for at least 12 lymph nodes to be examined before anyone can confidently say the nodes are clear. If your report shows fewer, ask whether that changes the staging conversation. An understaged cancer is an undertreated cancer.

Stage 0 is the most superficial lesion, limited to the mucosa. Because it has not invaded, the operation can be limited, sometimes to removal during colonoscopy.

Stage I means the tumor has reached the submucosa or the muscle layer but no nodes are involved. Standard treatment is surgical removal of the segment with clear margins, then joining the two ends back together, called anastomosis. Chemotherapy is not routine.

Here surgery is again the main treatment, wide removal and anastomosis. Whether to add chemotherapy afterward is still argued over, and the PDQ describes adjuvant chemotherapy for stage II as under clinical evaluation rather than standard.

Some stage II cancers carry higher risk. Features that raise concern include the tumor sticking to nearby structures, a perforation through the bowel wall, and complete obstruction at presentation.

Ask for MMR or MSI testing before this decision. Tumors that are dMMR or MSI-high behave differently, and the mismatch repair result is part of how oncologists weigh adjuvant therapy in stage II.

If you are offered chemotherapy for stage II, the fair question is: what is my estimated absolute benefit in percentage points, and over what time frame? A benefit of one or two points may or may not be worth six months of oxaliplatin, and that judgment belongs to you.

With positive lymph nodes, surgery alone leaves too much risk. The MOSAIC trial compared FOLFOX-4, which adds oxaliplatin to 5-FU and leucovorin, against the same regimen without oxaliplatin, over 6 months. FOLFOX produced longer overall survival in stage III.

That established oxaliplatin-based chemotherapy after surgery as the standard for stage III colon cancer.

The IDEA collaboration pooled six randomized trials, enrolling 13,025 people with stage III colon cancer between 2007 and 2015. It compared 3 months against 6 months of FOLFOX or CAPOX (capecitabine plus oxaliplatin).

Overall, 3 months did not formally prove non-inferior. Three-year disease-free survival was 74.6 percent with 3 months and 75.5 percent with 6 months.

The nerve damage difference is large. Grade 2 or worse neurotoxicity occurred in 16.6 percent on 3 months of FOLFOX and 14.2 percent on 3 months of CAPOX. On 6 months, the figures were 47.7 percent and 44.9 percent. Roughly a threefold difference, and this is the side effect most likely to be permanent.

The subgroup results split by regimen. With FOLFOX, 6 months was better than 3. With CAPOX, 3 months performed like 6.

So the real question to ask is not just "how long," but "which regimen, and at what risk level." IDEA was a pooled non-inferiority analysis rather than a rulebook, and its findings interact: the shorter course looked strongest with CAPOX and in lower-risk disease, defined by T and N stage. It does not translate into a fixed prescription. How long you are treated is a trade-off between a small difference in recurrence risk and a large difference in permanent nerve damage, weighed against your other health problems and what you want. Ask where your T and N stage puts you, which regimen is proposed, what the difference in benefit would be for you specifically, and say what you make of that trade.

Stage IV means spread beyond the colon and its nodes, most often to the liver.

Treatment options listed include surgery, systemic therapy, immunotherapy, and clinical trials. For liver-only disease, options include removing the metastases, chemotherapy first to shrink them so they become removable, local ablation, and chemotherapy delivered into the hepatic artery.

Before systemic treatment starts, tissue should be tested for MMR/MSI, RAS, BRAF, and HER2. Those results decide which antibody or targeted drug is added to chemotherapy.

• How many lymph nodes were examined, and how many were positive?
• Were the surgical margins clear, and by how much?
• Was there perforation, obstruction, or invasion into nearby structures?
• Has MMR or MSI testing been done, and what did it show?
• If chemotherapy is proposed, which regimen, how many months, and what is the estimated benefit for me?
• Who is following me afterward, and on what scan and blood test schedule?

• Belly pain with vomiting and no gas or stool passing.
• Fever of 100.4 F (38 C) or higher while on chemotherapy.
• Heavy rectal bleeding, or black tarry stools.
• A surgical wound that opens, drains, or becomes hot and red.
• New shortness of breath, or a swollen painful calf.

Metastatic Colorectal Cancer: What Now?, MSI-H Colorectal Cancer, Cancer Staging, and Chemotherapy.

• https://www.cancer.gov/types/colorectal/hp/colon-treatment-pdq
• https://seer.cancer.gov/statfacts/html/colorect.html